A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Mometasone and Formoterol Fumarate (Dulera)

First FDA approval2021-06-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$25.21/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$25.24
Across all dosage forms in distribution.
Highest NADAC
$25.30
Range is tight.
Plans with PA
63 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Mometasone and Formoterol Fumarate used for?

Mometasone and Formoterol Fumarate is a this drug class medication tracked in Medicare Part D.

Is there a generic for Mometasone and Formoterol Fumarate?

No. Mometasone and Formoterol Fumarate is brand-only with no generic equivalents currently in market.

How much does my plan pay for Mometasone and Formoterol Fumarate?

Across 329 Part D plans, Mometasone and Formoterol Fumarate averages $25.24/unit (NADAC). Lowest available: $25.21/unit. Highest in distribution: $25.30/unit.

Is Mometasone and Formoterol Fumarate on the FDA shortage list?

No. Mometasone and Formoterol Fumarate is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.